Solara Active Pharma Sciences Ltd Q4 FY25 Earnings Analysis
Published 15 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.1K Cr
Price
₹576
Market Cap
₹2.1K Cr
Earnings Summary
No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.
📊 Revenue & Sales Performance
No information is provided regarding the same in the latest conference call.
📈 Profitability & Margins
No information is provided regarding the same in the latest conference call.
🏗️ Capital Expenditure Plans
No information is provided regarding the same in the latest conference call.
💰 Fundraising & Capital Structure
No information is provided regarding the same in the latest conference call.
📋 Order Book & Pipeline
- The transcript does not explicitly mention the current or expected order book or pending orders for Solara Active Pharma Sciences Limited. - The company highlighted six key product approvals and 11 market extensions in Q3, focusing on portfolio maximization, new geographies, and new customers, which implies future order inflows. - The CRAMS business order pipeline seems positive with plans to grow revenue to approximately Rs. 500 crores in 3-4 years. - The Vizag CRAMS facility retrofit and investments suggest ongoing and future projects. - The company is focusing on cost improvements and margin expansion, implying they expect steady demand. - Overall, no quantitative order book details provided, but ongoing approvals and investments indicate a growing order pipeline.
Key Metrics
Frequently Asked Questions
What were Solara Active Pharma Sciences Ltd Q4 FY25 results?
No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.
What is Solara Active Pharma Sciences Ltd share price analysis?
Solara Active Pharma Sciences Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹2,098. Investors should review the full earnings analysis for detailed insights.
Is Solara Active Pharma Sciences Ltd planning capital expenditure?
No information is provided regarding the same in the latest conference call.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.